Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Neurocrine In "Hurry Up And Wait" Mode

"Long moments of boredom punctuated by moments of sheer terror" is a relatively common expression used in reference to war, but it can also apply to biotech investing, to a limited extent. Stocks like Neurocrine Biosciences (NASDAQ:NBIX) are inarguably driven in large part by relatively infrequent news on clinical trial outcomes and partnering arrangements, with the shares left to drift on speculation and overall biotech sentiment in the long spaces between.

Neurocrine management is certainly not just sitting on its hands as they work to put '854 into Phase III development for tardive dyskinesia and Phase II development for Tourette's, and as partner AbbVie (NYSE:ABBV) moves Elagolix through clinical trials in endometriosis and uterine fibroids. Between...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details